Biosimilars Market Analysis by Stages, Drug Class, and Phase of Development

The market is majorly driven by rising prevalence of chronic diseases, increasing investment in research and development (R&D) activities by biopharmaceutical companies, extensive pipeline of biosimilars, growing geriatric population, and inexpensive nature of biosimilars as compared to reference drugs.

< href="http://bit.ly/biosimilars-b">

On the basis of technology, the biosimilars market is categorized into five categories, such as monoclonal antibody (mAb), recombinant deoxyribonucleic acid (rDNA), bioassays, nuclear magnetic resonance (NMR), and electrophoresis. Biosimilars manufactured using mAb technology held the largest share, of 56%, in 2018. This technology is also expected to be the fastest growing category in the market, owing to large development of therapeutics with the help of this technology for various diseases such as cancer, immunological, and infectious diseases.

Moreover, companies in North America are more independent for pricing their products as compared to other regions, and trained scientific personnel and advanced technologies are readily accessible in North America, which make the region more suitable for pharmaceutical companies.

Request to Get the Sample Pages at:

New product launches and strategic collaborations play an important role in expansion of the biosimilars market. For instance, Amgen Inc. and EnteraBio Ltd. announced a collaboration to develop orally-administered formulation of biologics in 2018. This shows that companies are willing to invest in biologics, which in turn, is expected to be a major driving factor for the growth of the market.

Furthermore, in January 2019, Samsung Bioepis Co. Ltd. partnered with 3SBio Group to expand the biosimilar business in China. Through the partnership, Samsung Bioepis Co. Ltd. will be able to widen its biosimilars portfolio and 3SBio Group will be benefited from the sales of Avastin.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=biosimilars-market

In another strategic move, Celltrion Inc. in partnership with Teva Pharmaceutical Industries Ltd. announced the approval of Herceptin’s biosimilar, Herzuma, in October 2016. As a result, both companies got benefit from the sales of Herzuma. Also, Amgen Inc., Sandoz International GmbH, Samsung Bioepis, and Mylan N.V. jointly launched adalimumab in 2018 in the European biosimilars market and they are expected to launch this biosimilar in the U.S. market by 2023.

Some of the key players in the global biosimilars market are AMEGA Biotech, Samsung Bioepis Co. Ltd., Coherus BioSciences Inc., Synthon Holding B.V., BIOCAD, Zydus Cadila, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., and Mylan N.V.

BPH Procedures Market Comprehensive Review of its Top Companies, Trend, Growth Opportunities

Benign Prostatic Hyperplasia (BPH) Procedures are expected to grow at a CAGR of 2.3% during 2017 – 2023, according to P&S Market Research

Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care, since they are more prone to illness due to low immunity levels and longer recovery time.

Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, prostate implants and laser based treatments. Thus, growing aging population acts as a strong driver supporting the increase in the number of BPH procedures performed.

Download Report Sample at:

http://bit.ly/benign-prostatic-hyperplasia-procedures

Geographically, Europe accounted for the largest number of BPH procedures done in 2016. Growing ageing population, lower cost of BPH treatment as compared to the U.S., high healthcare spending, and technological advancements in the field of urological procedures technology are some of the factors driving the growth of the BPH procedures in the Europe. France, Germany and the U.K. are expected to be the most promising countries for the growth in number of the BPH procedures. In June 2016, National Institute of Health and Care Excellence (NICE) approved GreenLight XPS laser treatment for the treatment of BPH. NICE added that the widespread adoption of the procedure could save the National Health Services (NHS) an estimated $4.3 million (£3 million) a year. Asia-Pacific is expected to witness the high number of BPH procedures performed during the forecast period, owing to the rising prevalence of BPH disorders, increasing disposable income, aging population, and growing efforts to increase awareness about advanced BPH treatment procedures.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-procedures

Additionally, another example of technologically advanced BPH treatment devices include Dr Allen’s device for prostate care and ProVerum, which is used to restore function of the urethra in BPH to allow patients with this condition to urinate normally, relieving their symptoms while not interfering with sexual function. Dr Allen’s device uses thermobalancing therapy, which is different from other heating treatments as it does not regulate localized temperature.

Key players are in the process of introducing new advanced products for BPH treatment procedures. For instance, in May 2016, Olympus Corporation (Olympus), announced the launch of USFDA cleared Plasma-OvalButton, an addition to the company’s Plasma Loops and electrodes product portfolio that utilizes Olympus’ plasma technology for urologic procedures, including minimally invasive surgery to reduce benign prostate hyperplasia (BPH).

Some of the other key players operating in the global BPH procedures include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Karl Storz GmbH & Co. KG, Lumenis Ltd., Olympus Corporation, Advin Urology, Convergent Laser Technologies, Richard Wolf GmbH, Medtronic Plc.

Muscle Relaxant Drugs Market Worldwide Industry Analysis

The global muscle relaxant drugs market is growing, due to increasing aging population, increasing incidences of skin diseases and harmful effects of ultra violet radiation. In addition, the increasing usage of neuromuscular blocking agents in surgeries, and increase in disposable income are also driving the growth of the global muscle relaxant drugs market.

The information and data in the publication “Global Muscle Relaxant Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020” represent the research and analysis of data from various primary and secondary sources. The bottom-top approach has been used to calculate the global market size by type and drugs. The market numbers for countries are obtained through top-down approach.

Request to Get the Sample Pages at: 

http://bit.ly/muscle-relaxant-drugs-b

P&S Market Research analysts and consultants interacted with the authorities from leading companies of the concerned domain, to substantiate every value of data presented in this report. The company bases its primary research on discussions with prominent professionals and analysts in the industry, which is followed by informed and detailed, online and offline research.

The increasing aging population is propelling the growth of the global muscle relaxant drugs market, since the elder population is more prone to illness due to low immunity levels, and high recovery time consumption. Old age is associated with the loss of fibrous tissue, and reduced vascular and glandular network in the layers of skin. In the elderly population, the appearance and characteristics of the skin gets altered, leading to wrinkles, appearance of frown lines, dryness, pigmentary alteration, and sagging of the skin. The muscle relaxant-based procedures help in reducing skin aging, thus giving younger look to a person by revitalizing and tightening the skin.

However, the high capital expenditure, stringent regulatory requirements, and risks associated with muscle relaxants are inhibiting the growth of the global market. The tradition of online shopping for muscle relaxant drugs and their increasing usage in cosmetic industry are the major trends observed in the global muscle relaxant drugs market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=muscle-relaxant-drugs-market

Geographically, North America dominated the global market of muscle relaxant drugs in 2014; whereas the Asian market is expected to witness the fastest growth during the forecast period.

The key companies operating in the global muscle relaxant drugs market include F. Hoffmann-La Roche Ltd., Johnson & Johnson, GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Pfizer Inc., Galderma S.A., and Merck & Co. Inc.

Age-Related Macular Degeneration Market Changing Market Trends and Emerging Opportunities

Among the various types, the wet AMD segment is expected to witness the faster growth compared to dry AMD segment, during the forecast period. The global age-related macular degeneration market is growing at a significant rate, due to increasing healthcare cost, and increasing prevalence lifestyle associated diseases, such as obesity and hypertension. In addition, the growing geriatric population, increasing prevalence of AMD and increasing pipeline drugs for AMD are also driving the growth of the global age-related macular degeneration market.

The information and data in the publication “Global Age-related Macular Degeneration Market Size, Share, Development, Growth and Demand Forecast to 2022” represent the research and analysis of data from various primary and secondary sources. The bottom-top approach has been used to calculate the global market size by type. P&S Intelligence analysts and consultants interacted with authorities from leading companies of the concerned domain, to substantiate every value of data presented in the report. The company bases its primary research on discussions with prominent professionals and analysts in the industry, which is followed by informed and detailed, online, and offline research.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market/report-sample

Smoking, obesity, high blood pressure, high cholesterol, poor diet, ultra-violet radiation, hereditary, and light eye color are some of the risk factors associated with AMD. In early stages, macular degeneration may not have symptoms, although with the progress of the disease it may have symptoms such as deterioration in central vision or dark spot, and blurriness.

Factors such as stringent regulatory requirements and increase in off label use are inhibiting the growth of the global market. The increasing awareness of AMD is the key trend observed in the global age-related macular degeneration market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=age-related-macular-degeneration-market

Geographically, North America dominated the global market of age-related macular degeneration in 2015; whereas, the Asia-Pacific market is expected to witness the fastest growth, during the forecast period.

Some of the key companies operating in the global age-related macular degeneration market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences, Inc.